Which modifiers apply to 90471 claims
Feature: Targets: Semaglutide: GLP-1 Tirzepatide: GLP-1 + GIP Retatrutide: GLP-1 + GIP + Glucagon Max Weight Loss: Semaglutide: ~15% Tirzepatide: ~22% Retatrutide: 24.2%+ Energy Expenditure: Semaglutide: Low Tirzepatide: Moderate Retatrutide: High Muscle Preservation: Semaglutide: Moderate Tirzepatide: Moderate Retatrutide: Better Dosing Frequency: All: Weekly The addition of glucagon receptor activation gives Retatrutide a unique fat-burning advantage, making it ideal for visceral fat reduction and metabolic reset protocols
Studies show it protects against gastric ulcers, inflammatory bowel disease lesions, and NSAID-induced gut damage by enhancing mucosal integrity and blood vessel formation
Mounjaro (tirzepatide) is a prescription medicine licensed in the UK for the treatment of type 2 diabetes mellitus and, more recently, for weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
Applications: Drug management system: Artificial intelligence and a drug knowledge base form the foundation of an intelligent drug management system
Breakfast: Zucchini Bread Protein Mug Cake (microwave) 4 WW Points Lunch: Crispy Turkey Cottage Cheese Protein Crust Bites (oven 400F, or air fryer) GLP-1 friendly, meal-prep Dinner: Chinese Pineapple Chicken (stovetop) 3 SmartPoints (Blue/Purple) | 7 (Green) Saturday The only oven dinner of the week, and worth turning it on for at just 2 points
